Clinical Trials
16 trialsNCT02517918 2025-06-08
METZOLIMOS
Institut Bergonié
Phase 1 Completed
NCT03277924 2024-08-13
ImmunoSarc
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2 Completed
NCT01459484 2024-05-20
ISG/OS-2
Italian Sarcoma Group
Phase 2 Completed
NCT00667342 2023-08-07
A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT00134030 2023-06-07
EURAMOS-1
Children's Oncology Group
Phase 3 Completed
NCT00634504 2022-06-06
LVPK
BTG International Inc.
Phase 1 Completed
NCT01176981 2021-10-28
Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma
The Hospital for Sick Children
Phase 3 Completed
NCT01848457 2020-03-16
Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy
Children's Hospital of Philadelphia
Phase 2 Completed
NCT02383901 2016-09-05
FORTO
Isofol Medical AB
Completed
NCT00586846 2016-01-20
Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00742924 2014-07-04
Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
Children's Oncology Group
Phase 1 Completed
NCT00513981 2013-06-26
High-Dose Methotrexate in Treating Young Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00003776 2013-06-21
Combination Chemotherapy and Surgery in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00023998 2013-02-04
Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00119301 2013-01-17
Methotrexate, Trimetrexate Glucuronate, and Leucovorin in Treating Patients With Refractory or Recurrent Osteosarcoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00180908 2005-09-16
Comparison of High-Dose Methotrexate (HDM) Plus Doxorubicin to HDM Plus Etoposide-Ifosfamide in Osteosarcoma Children
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Completed